BioFilm Pharma : Bring to market the first-ever pure anti-biofilm, non-antibiotic drugs

BioFilm Pharma is our drug-discovery entity that aims to bring to market the first-ever pure anti-biofilm, non-antibiotic drugs, that prevent biofilm formation without killing bacteria.

These “anti-biofilms” are an entirely new class of drugs with the potential to transform the treatment of many chronic infections in first intention.

 With a capacity of thousands of tests per day, BioFilm Pharma leverages the power of the propietary automated BioFilm Ring Test to find desired antibiofilm properties among thousands of pre-qualified royalty-free molecules.

This unique biofilm detection technology capable of high throughput and high precision gives BioFilm Pharma a unique competitive advantage.

Target indications to date :

Drugs currently under development :

• Diabetic Foot Ulcer (27 million patients worldwide - 95 000 amputations / year in US+Europe countries)

• Lung infection in Cystic Fibrosis (65 000 patients worldwide - rare disease)

• Joint and Bones Infections (1 million patients worldwide)

Diabetic Foot Ulcer

Diabetic Foot Ulcer is a major complication for 20% of diabetes patients, with high morbidity and mortality rate (the 5-year mortality rate is of 25-50%). The chronicity of this infection is caused by biofilm.

Lung infection in Cystic Fibrosis

In lung infection in Cystic Fibrosis cases, bacteria spread in the mucus accumulated in lungs and damage the airways. Patients are on one or more antibiotics continuously for years, and these high intakes drive resistance and fosters growth of other pathogens.

Potential indications

Additional drugs will be developped in the future for the following indications :

• Urinary Tract Infections

• Wound Care : burn infections, Venous Ulcer Infections

• Lung Infections : Asthma-related infections, COPD infections, Non-Cystic Fibrosis bronchiectasis

Blockbuster drug potentials

While new antibiotics are indicated as last resort drugs, meaning low revenues, BioFilm Pharma dedicated antibiofilm drugs will be indicated as first intention for chronic bacterial infections, meaning potential blockbuster revenues (more than €1bn/year) – either as single treatments or as a co-drugs with antibiotics.

Low risk drug developments

2 main factors significantly reduce the risks of our current drug developments, as compared to other biotech projects :

1. We select only simple molecules that have already been tested on man for other applications (limited toxicity risk)

2. We have started with topical drugs (skin applicated) which limits the risks for the patient